|
Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness |
1K02DA054304-01A1 |
|
NIDA |
2022 |
|
Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities |
1K99DA056288-01 |
|
NIDA |
2022 |
|
Impact of Medicare Part D opioid safety policies on disabled beneficiaries before and during the COVID-19 pandemic |
1R01DA055131-01 |
|
NIDA |
2022 |
|
Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability |
1R01DA057568-01 |
|
NIDA |
2022 |
|
Social determinants of substance use disorder treatment outcomes in a vulnerable population |
1R21DA055229-01 |
|
NIDA |
2022 |
|
Deep Brain Stimulation (DBS) For Severe Treatment Refractory Methamphetamine Use Disorder |
1UG3DA054746-01A1 |
|
NIDA |
2022 |
|
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse |
2R01DA041931-07A1 |
|
NIDA |
2022 |
|
Neural circuitry mediating behavioral flexibility |
3R00DA042934-05S2 |
|
NIDA |
2022 |
|
Identification of small molecules for neurological complications of HIV and substance abuse comorbidity |
3R01DA046204-05S1 |
|
NIDA |
2022 |
|
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection-supplement |
3R01DA052845-03S1 |
|
NIDA |
2022 |